MA50943A - Anticorps anti-liv1 humanisés pour le traitement du cancer du sein - Google Patents
Anticorps anti-liv1 humanisés pour le traitement du cancer du seinInfo
- Publication number
- MA50943A MA50943A MA050943A MA50943A MA50943A MA 50943 A MA50943 A MA 50943A MA 050943 A MA050943 A MA 050943A MA 50943 A MA50943 A MA 50943A MA 50943 A MA50943 A MA 50943A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- breast cancer
- humanized anti
- liv1
- antibodies
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593660P | 2017-12-01 | 2017-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50943A true MA50943A (fr) | 2020-10-07 |
Family
ID=64746653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050943A MA50943A (fr) | 2017-12-01 | 2018-11-30 | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |
Country Status (14)
Country | Link |
---|---|
US (2) | US20200283540A1 (fr) |
EP (1) | EP3717518A1 (fr) |
JP (2) | JP2021505540A (fr) |
KR (1) | KR20200090838A (fr) |
CN (1) | CN111757892A (fr) |
AU (1) | AU2018375182A1 (fr) |
BR (1) | BR112020010937A2 (fr) |
CA (1) | CA3084495A1 (fr) |
EA (1) | EA202091360A1 (fr) |
IL (1) | IL274766A (fr) |
MA (1) | MA50943A (fr) |
MX (1) | MX2020005640A (fr) |
SG (1) | SG11202004751TA (fr) |
WO (1) | WO2019109007A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE48959E1 (en) | 2010-12-06 | 2022-03-08 | Seagen Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
AU2020318975A1 (en) * | 2019-07-22 | 2022-03-17 | Seagen Inc. | Humanized anti-LIV1 antibodies for the treatment of cancer |
MX2022006891A (es) * | 2019-12-09 | 2022-09-09 | Seagen Inc | Terapia combinada con liv1-adc y antagonista de pd-1. |
KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
WO2023241621A1 (fr) * | 2022-06-16 | 2023-12-21 | 山东博安生物技术股份有限公司 | Anticorps anti-liv-1 et conjugué anticorps-médicament |
WO2024165056A1 (fr) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Anticorps ciblant liv-1 et leurs utilisations |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
FI102355B (fi) | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
EP2298809A3 (fr) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Anticorps super humanisés |
HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
WO2004067564A2 (fr) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions contre l'antgene cancereux liv-1 et leurs utilisations |
DK2489364T3 (en) * | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
AU2006269422B2 (en) | 2005-07-07 | 2012-12-06 | Seagen Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
TW200813231A (en) * | 2006-04-13 | 2008-03-16 | Novartis Vaccines & Diagnostic | Methods of treating, diagnosing or detecting cancer |
DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
USRE48959E1 (en) | 2010-12-06 | 2022-03-08 | Seagen Inc. | Humanized antibodies to LIV-1 and use of same to treat cancer |
WO2013170263A2 (fr) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage et administration de conjugués scfv bispécifiques en combinaison avec des agents thérapeutiques anticancéreux |
US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US20150343077A1 (en) * | 2014-05-13 | 2015-12-03 | Immunogen, Inc. | Anti-CD37 Immunoconjugate Dosing Regimens |
MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
-
2018
- 2018-11-30 CN CN201880077514.3A patent/CN111757892A/zh active Pending
- 2018-11-30 WO PCT/US2018/063425 patent/WO2019109007A1/fr unknown
- 2018-11-30 MX MX2020005640A patent/MX2020005640A/es unknown
- 2018-11-30 AU AU2018375182A patent/AU2018375182A1/en active Pending
- 2018-11-30 JP JP2020529281A patent/JP2021505540A/ja active Pending
- 2018-11-30 KR KR1020207017651A patent/KR20200090838A/ko not_active Application Discontinuation
- 2018-11-30 BR BR112020010937-1A patent/BR112020010937A2/pt unknown
- 2018-11-30 SG SG11202004751TA patent/SG11202004751TA/en unknown
- 2018-11-30 EA EA202091360A patent/EA202091360A1/ru unknown
- 2018-11-30 MA MA050943A patent/MA50943A/fr unknown
- 2018-11-30 EP EP18822563.5A patent/EP3717518A1/fr active Pending
- 2018-11-30 US US16/768,020 patent/US20200283540A1/en not_active Abandoned
- 2018-11-30 CA CA3084495A patent/CA3084495A1/fr active Pending
-
2020
- 2020-05-19 IL IL274766A patent/IL274766A/en unknown
-
2023
- 2023-03-07 US US18/179,560 patent/US20240076402A1/en active Pending
- 2023-10-06 JP JP2023173950A patent/JP2024001187A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20200090838A (ko) | 2020-07-29 |
CN111757892A (zh) | 2020-10-09 |
BR112020010937A2 (pt) | 2020-11-17 |
US20200283540A1 (en) | 2020-09-10 |
IL274766A (en) | 2020-07-30 |
US20240076402A1 (en) | 2024-03-07 |
JP2021505540A (ja) | 2021-02-18 |
MX2020005640A (es) | 2020-08-20 |
AU2018375182A1 (en) | 2020-06-11 |
WO2019109007A1 (fr) | 2019-06-06 |
EP3717518A1 (fr) | 2020-10-07 |
SG11202004751TA (en) | 2020-06-29 |
CA3084495A1 (fr) | 2019-06-06 |
JP2024001187A (ja) | 2024-01-09 |
EA202091360A1 (ru) | 2020-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA47776A (fr) | Polythérapies pour le traitement du cancer du sein | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
IL274813A (en) | A liquid preparation of a humanized antibody for the treatment of 6-IL-related disease | |
MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
MA46361A (fr) | Traitement du cancer de la prostate |